<img src="https://ml.globenewswire.com/Resource/Download/ebf510d7-3727-4cc8-894f-6ce2d82b941a?size=2" nborder="0" align="left" hspace="5" vspace="5" title="Kura Logo for Globe newswire PRs.png" alt="Kura Oncology, Inc."/>SAN DIEGO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report its second quarter 2026 financial results after the close of the U.S financial markets on Wednesday, August 12, 2026. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and provide a corporate update. The live webcast and archived replay of the event may be accessed on the Company’s website at <a href="https://www.globenewswire.com/Tracker?data=xbdso00o2YsM2jNjL8dgzwbSRFuFmgnrzhQIoliGA4a9VxDUofsMTN188JdK4xL7tH-Ku9j9aXr-wuGgipHgMcpW9ZiIF-RrNU1CaAJcojI=" rel="nofollow" target="_blank" title="www.kuraoncology.com">www.kuraoncology.com</a> under the Investors tab in the Events and Presentations section. About Kura Oncology Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at <a href="https://www.globenewswire.com/Tracker?data=ufkZH6r-IKDYF7T7QLOL25zVTMUEI1VouquWT6LR0GMmVcF8Ld71R_VPhxIFJbf7hKE_osblOzw6b4vzDzEiSXVCO1O9dAwM5J6Z10uC994=" rel="nofollow" target="_blank" title="">https://kuraoncology.com/</a> and follow us <a href="https://www.globenewswire.com/Tracker?data=x4T4rngWHPukpmSbCDPLhPX7yv21uwKQgI2iv7tkLwxKe-T3v8vFBPz-CiL_CV_eyiPGr52PQDx0tKco5SQWbs6s7J06VwW4yg7mSyXNrrHpnlrRayj0gR28m7E0XLUj8rXExNyGKn92VVRU0BsX6_ofpWG-c0D7OF4kYZmYLiSZIdF-Verpykt51S0d7tb6UHF0-ee0HT4rOhyDGdUiEg==" rel="nofollow" target="_blank" title="X">X</a> and <a href="https://www.globenewswire.com/Tracker?data=GmRkNXoalJXDInFfljOkgL-1uEJe50Bniy4LznN-17c9LWE7k0d15rHPs52mbvHzKMB4I1ChlPIx7BAPWWZfrh5AUJA3gxsZ0QeIwO_sJg45zWsBUe0UQ9f_TKtxWrxtPkyxd-58LyhY5Wkj7qc0HZT-P97kzHlpJ9tGlbky4gtiMUdUeFIqoudD5S8CVP2qH1Nx-H9O3HttgkA2Be960D60562q9tFbgYoSKmrj6A4CuANWG9NyZFc4Ade5rzqA_t3KjdqLNyODlwr2ILNHnw==" rel="nofollow" target="_blank" title="LinkedIn">LinkedIn</a>. Kura Contact Investors and Media: Greg Mann 858-987-4046 <a href="https://www.globenewswire.com/Tracker?data=NjbQk41dSWyvLXkrhMvvlpO2nxFDKjQCBwGDVpn7sKaz3tmgcGCF174OR2mH7-xGxw0X3y23ZLsTcXvAKbFyd_elhDa2ArW0Z8PIhfmA_Xc=" rel="nofollow" target="_blank" title="gmann@kuraoncology.com">gmann@kuraoncology.com</a> <img alt="" src='https://ml.globenewswire.com/media/ZDI3YTk1NTEtOGY3Ny00ZTVkLTkwNTUtZDEzYTI0MTkzMzMwLTEwMjg3NjgtMjAyNi0wOC0wNS1lbg==/tiny/Kura-Oncology-Inc-.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Kura Oncology to Report Second Quarter Financial Results

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn